Ionis Pharmaceuticals, Inc. Share Price

Equities

IONS

US4622221004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:18:19 17/06/2024 pm IST 5-day change 1st Jan Change
40.77 USD +0.30% Intraday chart for Ionis Pharmaceuticals, Inc. +2.41% -19.45%
Sales 2024 * 598M 49.93B Sales 2025 * 767M 64.04B Capitalization 5.93B 495B
Net income 2024 * -573M -47.85B Net income 2025 * -520M -43.42B EV / Sales 2024 * 9.35 x
Net cash position 2024 * 335M 28B Net Debt 2025 * 72.35M 6.04B EV / Sales 2025 * 7.82 x
P/E ratio 2024 *
-10.7 x
P/E ratio 2025 *
-12.3 x
Employees 927
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.30%
1 week+2.41%
Current month+8.46%
1 month+9.22%
3 months-3.05%
6 months-19.64%
Current year-19.45%
More quotes
1 week
39.26
Extreme 39.255
41.80
1 month
35.95
Extreme 35.95
41.80
Current year
35.95
Extreme 35.95
54.44
1 year
35.95
Extreme 35.95
54.44
3 years
25.04
Extreme 25.04
54.44
5 years
25.04
Extreme 25.04
73.09
10 years
19.59
Extreme 19.5927
86.58
More quotes
Managers TitleAgeSince
Founder 58 01/12/01
Founder 62 10/89/10
Director of Finance/CFO 62 01/00/01
Members of the board TitleAgeSince
Chairman 72 03/14/03
Founder 62 10/89/10
Director/Board Member 70 10/19/10
More insiders
Date Price Change Volume
17/24/17 40.76 +0.27% 246 998
14/24/14 40.65 -1.14% 1,392,008
13/24/13 41.12 -0.92% 861,497
12/24/12 41.5 +4.56% 1,280,318
11/24/11 39.69 -0.25% 857,905

Delayed Quote Nasdaq, June 17, 2024 at 11:03 pm IST

More quotes
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
40.65 USD
Average target price
58.04 USD
Spread / Average Target
+42.77%
Consensus